Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Psoriasis
•
Dermatology
•
Primary Care
•
Viral Hepatitis
Do you caution against starting biologics for psoriasis if patient has hepatitis A antibodies?
Answer from: at Academic Institution
No
Comments
at Jefferson Regional Medical Center
No
12435
Sign In
or
Register
to read more
23143
Related Questions
How would you manage active severe psoriasis in a patient planning pregnancy, who also has psoriatic arthritis with well-controlled joint symptoms on certolizumab pegol (anti-TNF therapy)?
What treatment options would you recommend for a patient with severe generalized pustular psoriasis who has a history of colon cancer (s/p chemotherapy) and well-controlled HIV?
What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for the management of psoriasis and/or psoriatic arthritis?
Can inflammatory arthritis develop in patients with a history of chronic hepatitis B?
How do you approach management of a patient with coexisting psoriasis and systemic sclerosis, particularly when both active psoriasis and skin tightening are present?
Would oral roflumilast be a reasonable and tolerable option for severe psoriasis in an elderly patient with a history of pulmonary aspergillosis who has failed other systemic therapies?
How would you manage a patient with nonspecific clinical symptoms and pathology consistent with spongiotic and psoriasiform dermatitis other than oral JAK inhibitors?
What are your recommendations for managing perivascular dermatitis with eosinophils unresponsive to high-dose antihistamines, a prednisone taper, and topical steroids?
What therapies have you found most effective for JAK-induced/associated acne (JAKcne)?
What patient factors do you feel are most important when considering reduced dosing regimens of IL17a inhibitors such as secukinumab and ixekizumab for psoriasis?
No